Literature DB >> 1085753

Platelet aggregation by hepatitis B surface antigen-antibody complexes.

H Daugharty, R Gogel.   

Abstract

Platelet aggregation indicating antigen-antibody complex formation was observed when hepatitis B surface (HBs) antigen and antibody were mixed. Platelet aggregation titers were determined for serum specimens found positive by radioimmunoassay for either HBs antigen or HBs antibody. From these determinations, incidence of HBs antigen-antibody complexes was found to be higher in HBs antigen seraas than in HBs antibody sera. There was an inverse correlation between platelet aggregation titers and radioimmunoassay values that was statistically significant for HBs antigen sera but not for HBs antibody sera. The incidence of anti-complementary activity was twice as high for platelet aggregation-positive HBs antigen and antibody sera as for platelet aggregation-negative sera. HBs antigen sera that were positive by platelet aggregation exhibited nearly three times the incidence of anti-complementary activity as did HBs antibody sera. However, the low incidence of anti-complementary activity was distributed about equally between HBs antigen and antibody sera that were negative by platelet aggregation. Additional HBs antigen preincubated with HBs antigen-positive sera effectively inhibited platelet aggregation, whereas additional HBs antibody was somewhat less effective. On the other hand, preincubation of HBs antigen sera with anti-IgG serum effectively enhanced platelet aggregation, whereas preincubation of HBs antigen sera with HBs antibody did not.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1085753      PMCID: PMC420950          DOI: 10.1128/iai.14.3.752-758.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

Review 1.  Aleutian disease in mink: virology, immunology and pathogenesis.

Authors:  D G Ingram; H J Cho
Journal:  J Rheumatol       Date:  1974-03       Impact factor: 4.666

2.  Aggregation of human blood platelets by immune complexes in the sedimentation pattern test.

Authors:  G Myllylä
Journal:  Scand J Haematol Suppl       Date:  1973

3.  Detection and characterization of immune complexes by the platelet aggregation test. II. Circulating complexes.

Authors:  G Myllylä; A Vaheri; K Penttinen
Journal:  Clin Exp Immunol       Date:  1971-03       Impact factor: 4.330

4.  Detection of Au(1) antigen by immunodiffusion and platelet aggregation tests.

Authors:  L Melartin; G Myllylä; K Penttinen
Journal:  Vox Sang       Date:  1970 Sep-Oct       Impact factor: 2.144

5.  Virus-like antigen, antibody, and antigen-antibody complexes in hepatitis measured by complement fixation.

Authors:  N R Shulman; L F Barker
Journal:  Science       Date:  1969-07-18       Impact factor: 47.728

6.  Immune complexes in hepatitis.

Authors:  J D Almeida; A P Waterson
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

7.  Interactions of standard antibody with Australia antigens in Au Ag-Ab radioimmunoassay.

Authors:  H Daugharty; R G Young; M H Hatch; D W Ziegler
Journal:  Appl Microbiol       Date:  1974-04

8.  Circulating immune complexes in Mycoplasma pneumoniae infection.

Authors:  G Biberfeld; R Norberg
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

9.  Effects of antigen-antibody complexes on the primary immune response in Rhesus monkeys.

Authors:  W E Houston; C E Pedersen; F E Cole; R O Spertzel
Journal:  Infect Immun       Date:  1974-09       Impact factor: 3.441

10.  Antibody to leukemia virus: widespread occurrence in inbred mice.

Authors:  R C Nowinski; S L Kaehler
Journal:  Science       Date:  1974-09-06       Impact factor: 47.728

View more
  2 in total

1.  HBsAg immune complexes in the course of infection with hepatitis B virus.

Authors:  K Madaliński; I Bragiel
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

2.  Autoimmune implications of immune complexes in clinical variants of hepatitis B.

Authors:  H Daugharty; K Kelley; C Moore; T Hersh
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.